Direct-to-consumer pharmacogenomic testing

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1367-1370

  Howard, Heidi Carmen ^a,b   Borry, Pascal ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

direct to consumer genetic testing; disclaimers; medical supervision; pharmacogenomics

Indexed keywords

ABACAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLOPIDOGREL; DNA; RNA; TAMOXIFEN; WARFARIN;

ADVERSE DRUG REACTION; CONSUMER; DEVICE; DIRECT TO CONSUMER GENETIC TESTING; DIRECT TO CONSUMER PHARMACOGENOMIC TESTING; DOCTOR PATIENT RELATION; DRUG COST; DRUG RESPONSE; GENETIC SCREENING; HEALTH CARE PERSONNEL; HUMAN; INDUSTRY; MARKETING; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; REVIEW; SCREENING;

CONSUMER PARTICIPATION; DELIVERY OF HEALTH CARE; GENETIC TESTING; HUMANS; PHARMACOGENETICS;

EID: 80054963744     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.100     Document Type: Review

References (17)

1. Mitchell PB, Meiser B, Wilde A et al. Predictive and diagnostic genetic testing in psychiatry. Clin. Lab. Med. 30(4), 829-846
2. Howard HC, Borry P. Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context. J. Commun. Genet. Rev. (2011) (In Press).
3. Berg C, Fryer-Edwards K. The ethical challenges of direct-to-consumer genetic testing. J. Business Ethics 77, 17-31 (2008).
4. Howard HC, Borry P. Personal genome testing: do you know what you are buying? Am. J. Bioeth. 9(6-7), 11-13 (2009).
5. Janssens AC, Gwinn M, Bradley LA, Oostra BA, Van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am. J. Hum. Genet. 82(3), 593-599 (2008). (Pubitemid 351726114)
6. Mihaescu R, Van Hoek M, Sijbrands EJ et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet. Med. 11(8), 588-594 (2009).
7. Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet. Med. 11(8), 570-574 (2009).
8. Wade CH, Wilfond BS. Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests. Am. J. Med. Genet. C Semin. Med. Genet. 142C(4), 284-292, discussion 293 (2006). (Pubitemid 44747456)
9. Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet. 9, 161-182 (2008).
10. Howard HC, Avard D, Borry P. Are the kids really all right? Eur. J. Hum. Genet. DOI: 10.1038/ejhg.2011.94 (2011) (Epub ahead of print).
11. Mcguire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300(22), 2669-2671 (2008).
12. Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet. Med. 10(6), 391-395 (2008).
13. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet. 4(4), 204-214 (2001). (Pubitemid 34762158)
14. Borry PB, Cornel MC, Howard HC. Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J. Commun. Genet. 1(3), 101-106 (2010).
15. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am. J. Bioeth. 9(6-7), 3-10 (2009).
16. European Society of Human Genetics (ESHG). Statement of the ESHG on direct-to-consumer genetic testing for health purposes. Eur. J. Hum. Genet. 18, 1271-1273 (2010).
17. Wallace H. Most gene test sales are misleading. Nat. Biotechnol. 26(11), 1221 (2008).